Register for our free email digests:
Division of Abbott Laboratories Inc.
Latest From Endosense SA
Cardiac rhythm management device sales in the US are projected to grow at a compound annual rate of 2.9%, increasing to an estimated $8.2 billion in the year 2019. Two of the fastest growing sectors of the market, electrophysiology and ablation devices, will be driven by a 10% to 20% growth in the number of patients treated for atrial fibrillation.
The diversified company is entering the atrial fibrillation catheter ablation for the first time. It is acquiring Afib ablation mapping system maker Topera and has gained rights to buy catheter developer Advanced Cardiac Therapeutics.
The TactiCath Quartz irrigated ablation catheter, acquired in the Endosense deal in 2013, lets electrophysiologists monitor the force exerted by the catheter tip on the endocardium during an atrial fibrillation ablation procedure.
To stave off the sluggish growth in established markets, multinational medtechs not only are finding new business in countries with booming health care industries but they’re also forging new ways to serve customers. Device companies now are pushing into services, such as disease management, and angling to compete more aggressively on pricing.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Abbott Laboratories Inc.
- Senior Management
Nicolas Marsault, CFO
Laurent Grandidier, VP, Sales & Mktg.
- Contact Info
Phone: (41) 22 306 1960
Chemin du Grand-Puits 42
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.